anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To simply form a fine marble pattern having high sensuousness on the surface of a cosmetic.  <P>SOLUTION: A plurality of slurry cosmetics having different color tones are packed into a cosmetic dish 2. Wire rods 4b arranged facing the opening part of the cosmetic dish 2 are inserted into the cosmetic dish 2. The packed material in the cosmetic dish 2 is stirred by relative displacement between the wire rods 4b and the cosmetic dish 2 to form a marble pattern. After removal of the wire rods 4b inserted into the cosmetic dish 2, the stirred packed material in the cosmetic dish is pressed.  <P>COPYRIGHT: (C)2010,JPO&INPIT
An intelligent service platform includes an input module, a deep learning engine based on a human thinking deep learning model, and an output module. The input module is configured to receive user-related information collected by the intelligent service terminal. The deep learning model describes the way the brain encodes information, and the human thinking deep learning model is trained on individual-related historical data and further adjusted in use by individual daily responses collected by the intelligent service terminal. The deep learning engine is further configured to identify an intent or emotion of the user from the received user-related information and generate a corresponding response or command output. The output module may be configured to provide a corresponding response or command output to the intelligent service terminal. With embodiments of the present disclosure, the deep learning model may be trained based on individual-related historical data and further adjusted in use by individual daily responses collected by the intelligent service terminal, and thus the robot may learn from the user daily and output appropriate commands or responses to the respective user accordingly, without the need for predefined instructions and messages.
The present invention relates to binding molecules specific for IL-21 and uses thereof. The present disclosure provides IL-21 binding molecules, such as anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects, anti-IL-21 antibodies and antigen-binding fragments thereof can be hybridoma-derived murine monoclonal antibodies and humanized versions thereof. In certain aspects, binding molecules, such as the anti-IL-21 antibodies and antigen-binding fragments thereof provided herein, inhibit, suppress, or antagonize IL-21 activity. In addition, the present disclosure provides compositions and methods for diagnosing and treating diseases or disorders, such as inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the present disclosure provides methods of treating or preventing Graft Versus Host Disease (GVHD) using IL-21 binding molecules, such as anti-IL-21 antibodies and antigen-binding fragments thereof.
PURPOSE:To obtain a tablet of a foamable composition storable stably until it is used by a consumer, by mixing an organic acid with polyethylene glycol in molten state, cooling and pulverizing the mixture, adding sodium (bi)carbonate thereto, and tableting the composition. CONSTITUTION:The objective tablet can be produced by mixing (A) 100pts.wt. of an organic acid essentially devoid of water of free from isolation of the water of crystallization at <=50 deg.C (e.g. citric acid, malic acid, succinic acid, etc.) with (B) preferably 2-10pts. of a plyethylene glycol (preferably having an average molecular weight of 4,000-20,000) under melting, cooling and pulverizing the mixture, adding sodium carbonate, sodium bicarbonate or other component thereto and tableting the obtained composition. When the above mixture is brought into contact with carbon dioxide gas, 1mol of sodium carbonate is converted to 2mol of sodium bicarbonate by the reaction with 1mol of water and 1mol of carbon dioxide gas. Accordingly, the water-content in the system is lowered and the stability of the product is further improved.
The present invention comprises reagents and methods which target actin filaments or the cellular signals that control actin filament integrity. Specifically, the invention provides novel actin binding polypeptides (e.g., human AFAP polypeptides), antibodies which specifically recognize the same, nucleic acids encoding the same, and methods for using these polypeptides, antibodies, and nucleic acids. Such reagents are useful for the diagnosis, prognosis and treatment of cancer, and in the research and development of anti-cancer diagnostic and therapeutic agents. Such reagents are useful for treatment of conditions associated with aberrant angiogenesis, for example, obesity. In one aspect, model animals are provided comprising AFAP regulatory sequences operably linked to reporter molecules. These animals provide a system in which to study the affect of agents on neural development.
The application discloses a value range data matching method, a value range data matching device and related products. Obtaining the surgical name to be matched in the value range data to be matched; processing the surgical name to be matched to obtain a feature vector group to be matched; and obtaining a matching result by utilizing the pre-trained data matching model and the feature vector set to be matched. Therefore, the data matching model obtained through training has the function of matching the national standard operation name according to the operation name which is not the national standard, can determine the specific classification condition of the national standard operation name in the value range classification tree, and reflects the specific classification condition through the node index value. The matching result can be used for indexing and obtaining the national standard operation name matched by the operation name to be matched, and determining the specific classification condition of the matched national standard operation name in the value domain classification tree. Compared with the prior art, the matching device has the advantages that manual labor is effectively saved, and matching efficiency is improved. In addition, the anti-interference performance of matching can be improved, and the matching accuracy of the value range data is further improved.
PURPOSE: To obtain capsules containing a pharmaceutically effective agent, capable of inducing an elusion of the pharmaceutically effective agent with simple reusing of a solvent at a low cost by controlling the elusion of the pharmaceutically effective agent in water from capsules containing the pharmaceutically effective agent. CONSTITUTION: This production of capsules containing a pharmaceutically effective agent is to dissolve a coating material consisting of a water insoluble material (e.g.; paraffin wax) in a solvent having 10-35 dielectric constant such as ethanol, agitate the solution with particles of the pharmaceutically effective agent at 30 deg.C, cool the obtained suspension at a speed of 0.001-10 deg.C/min., precipitate the water insoluble material, coagulate the water insoluble material on the particle surface of the pharmaceutically effective agent, remove the solvent from capsules containing the pharmaceutically effective agent, dry the capsules to form coating layer on the particle surface of the pharmaceutically effective agent and obtain the objective capsules.  Further, an elusion inhibiting effect of the pharmaceutically effective agent can be enhanced by heat treating the obtained capsules and bringing the coated layer denser. A mechanical strength of the capsule should be 1-200g/unit in crushing strength. The capsules are used by blending with a teeth paste, a shampoo, a liquid detergent, etc.
All study participants will receive vitamin D supplementation (soft gel capsule containing cholecalciferol 400 IU) to be consumed 2 soft gel capsules daily for three consecutive months. The effect on the platelet parameters specified above will be determined before start cholecalciferol supplementation and after three months.
PURPOSE:The titled composition consisting essentially of a partial hydrolyzate of gelatin linked to a diisocyanate in the form of an aqueous solution or useful therefor. CONSTITUTION:A composition, containing a tissue plasminogen activating factor (tPA), i.e. a substitute blood plasma component without antigenicity obtained by partially hydrolyzing gelatin to give as a low-molecular polypeptide and linking the resultant polypeptide to a diisocyanate and having 35,000 average molecular weight as an essential component in the form of an aqueous solution or useful therefor. If the concentration of the tPA is high, the viscosity of the aqueous solution is increased to make the handling difficult. The tPA is incorporated to give preferably <=10%, more preferably <=5% concentration when used as an aqueous solution. A saccharide or amino acid may be freely incorporated to give a freeze-dried pharmaceutical.
A make-up product for the lips comprises a powder contained in a receiver which is deposited on the lips by means of an applicator the powder is compacted in the container and contains 15-40% of a mixture of fats and/or waxes, pref. 30%. The product is a replacement for lipstick compsn. is better compacted resulting in less losses on application with easier and more uniform spreading on the lips. The adhesion is good and the application comfortable,. Various types of applications may be used unlike previous products which required a foam applicator giving a harsh feel.
The goal of the present exploratory investigation is to see if there is a suggestion of a large additive or synergistic effect of melatonin and donepezil given together. Individually both medications improve sleep, but appear do so in different ways, with melatonin altering circadian rhythm and donepezil altering the characteristics of REM sleep. In this pilot investigation we will examine whether their combined effects on sleep lead to a large improvement in the behavior of children with ASD. Combined pharmacotherapy is very common in clinical practice, but is rarely studied in research (Comer et al. 2010). These two medications are both well tolerated and there is no negative drug interaction between the two. This investigation will use an RCT as well as a set of exploratory analyses to assess the combined effects of these two medications compared to placebo in terms of behavioral and sleep measures. In addition we will collect exploratory biomarkers (e.g., digit ratio, the ratio of the lengths different fingers as a measure of the balance of sex hormones during embryonic development) to relate to the various sleep and behavioral measures. A positive signal from this study may be used to guide a follow-up study with greater numbers of study subjects and statistical power.
Fluocinonide cream, 0.1% contains fluocinonide, a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and antipruritic agents. Fluocinonide has the chemical name 6 alpha, 9 alpha-difluoro-11 beta, 21-dihydroxy-16 alpha, 17 alpha-isopropylidenedioxypregna-1, 4-diene-3,20-dione 21-acetate. Its chemical formula is C26H32F2O7 and it has a molecular weight of 494.58.

It has the following chemical structure:

Fluocinonide is an almost odorless white to creamy white crystalline powder. It is practically insoluble in water and slightly soluble in ethanol.

Each gram of fluocinonide cream contains 1 mg micronized fluocinonide in a cream base of anhydrous citric acid USP, carbomer 980 NF, diisopropanolamine, diethylene glycol monoethyl ether, glyceryl monostearate NF, glyceryl stearate (and) PEG-100 stearate, propylene glycol USP, and purified water USP.
Investigators will send the PCP via secure email the patient's prognosis calculated by the Lee-Schonberg index three days before the patient visit. Investigators will also send PCPs information on patient life expectancy from Cho et al.'s US life tables and scripts developed to sensitively include information on patient prognosis when recommending patients stop being screened for cancer. After five of their patients have participated or recruitment goals are met, investigators will ask PCPs to complete a 10 minute web-based questionnaire about their experience.
An allergenically active water-insoluble complex is prepared by treating the whole of an allergen material with an extracting liquid comprising a heterocyclic tertiary amine and an aqueous medium, filtering the aqueous extract so formed and adding alum to precipitate a water - insoluble complex.  The heterocyclic amine may be pyridine, lutidine or quinoline.  The aqueous medium may be a solution of sodium bicarbonate, sodium chloride and sodium hydroxide in water at pH 7.0.  The alum solution is preferably in acidic solution.  The precipitated complex is suspended in isotonic saline solution for administration by injection especially for the treatment of asthma and hay-fever.  The allergen may be (a) an inhalant allergen, e.g. dust, animal skin, hair, fur or feathers, seeds and particles from the breakdown of the bodies of insects and the pollen of weeds, grasses or trees, or (b) contact allergen, e.g. rabbit fur and cat fur, which by contact with sensitive individuals produces an allergen reaction, or a stinging insect.
Participants will receive 5.6 mg/kg U3-1402 (Patritumab Deruxtecan) intravenously on day 1 every 3 weeks. All participants will undergo pre-treatment biopsies. (An archival tissue sample taken within two months of treatment should be provided if it is not medically feasible to provide a pre-treatment biopsy). Up to 60 participants will be enrolled into this arm.
PROBLEM TO BE SOLVED: To obtain a cleaner composition for bodies, containing biodegradable plastic powder having a prescribed average particle diameter, excellent in a cleaning force, weak in the irritation of skins, good in biodegradability and substantially not causing environmental pollutions. SOLUTION: This cleaner composition for bodies contains biodegradable plastic powder having an average particle diameter of 30-500μm, preferably 100-300μm. The biodegradable plastic is preferably an aliphatic polyester (e.g. polyglycolic acid ester). The cleaner composition for bodies preferably contains biodegradable plastic powder having an average particle diameter of 30-500μm (0.5-30wt.%), a terpene hydrocarbon and/or a terpene alcohol (0.5-30wt.%) and a surfactant (0.5-30wt.%), and preferably has a viscosity of 5-100 poise at 20 deg.C. The composition can effectively remove strong stains such as heavy oil stains, metal powder stains or coating film-like stains in industrial production sites, etc., and is especially suitable as a hand cleaner.
PROBLEM TO BE SOLVED: To obtain a cosmetic containing a powder capable of allowing a person having a sensitive skin to use the cosmetic without anxiety by including two components of an alkyl-modified carboxy polymer and a nonionic surfactant having a specific properties. SOLUTION: This cosmetic contains (A) an alkyl-modified carboxy polymer and (B) one or more kinds of nonionic surfactant having fluidity at 25 deg.C under 1 atm, and 3-7 HLB (preferably glyceryl oleate, sorbitan oleate or the like). The content of the component A is preferably 0.01-5 wt.% based on the whole amount of the cosmetic. The content of the component B is preferably 0.01-1 wt.%. Preferably, the cosmetic further contains >=5 wt.% metal oxide including titanium. The cosmetic is preferably regulated so as to have pH <7. As the result, a makeup cosmetic such as foundation used by a person having a sensitive skin without anxiety is expected.
Experimental group will include postmenopausal women who will practice following exercise program:aerobic exercise, resistance training and balance exercise. Aerobic exercise will be conducted as a dose walk, 3-5 km / h, approximately 70% of maximal heart rate, about 50 minutes per day, five days per week, for 12 weeks. Resistance training and balance exercises will be conducted as a group program and will involve exercises to strengthen the muscles of the upper and lower extremities and balance exercises. The intensity of the training will be increased weekly, starting from 3-5 repeating load and its own weight, up to 8-12 repetitions with straps. Frequency of training will be 3 times per week, will last 70 minutes per day, for 12 weeks.
PURPOSE: The purpose of this study was to evaluate the ischemic penumbra and prognosis in acute cerebral infarction using cerebral blood flow (CBF) and delay time (DT) derived from multi-delay pseudo-continuous arterial spin-labeling (pCASL) imaging and to estimate the possible use of such indices to predict prognosis.
METHOD: Our subjects comprised 25 patients who were diagnosed with cerebral infarction in our stroke center between September 2017 and December 2018 and underwent pCASL perfusion MRI. The time from onset to MRI was 0.6 to 20 h (mean, 6 h) and was less than 4.5 h in 16 patients. Twelve patients received conservative treatment, three were treated with tPA, and the remaining 10 patients underwent invasive treatment (e.g., thrombectomy). They were subdivided by recanalization:18 patients were non-recanalized and 7 were recanalized. We evaluated the mean cerebral blood flow (CBF) and mean arterial transit DT at the infarct core and penumbra and the infarct size at the initial and follow-up examinations and calculated the infarct enlargement ratio (ER) from the initial and final infarct sizes. We also assessed clinical prognosis by using the initial and final NIHSS scores. We investigated the relationship among the ASL, ER, and NIHSS parameters and determined predictors of infarct enlargement using logistic analysis.
RESULT: The degree of the CBF decrease was related to the size of the initial infarct lesion (CBF at core:r=-0.4060, p=0.044;CBF at penumbra:r=-0.4970, p=0.012) and initial NIHSS (r=-0.451, p=0.024;CBF at penumbra:r=-0.491, p=0.013). Because no parameters were correlated with the ER in all patients. Specifically in the non-recanalization group, the DT at the penumbra was positively correlated with the ER (r=-0.496, p=0.034). Moreover, by logistic regression analysis, the DT at the penumbra was the only independent predictor of infarct enlargement in all patients (p=0.047) and in non-recanalization patients (p=0.036).
CONCLUSION: The only parameter predicting the ER was the mean DT at the penumbra, and the tendency was affected by recanalization status. DT obtained by multi-delay ASL may become a prognostic index of acute cerebral infarction. J. Med. Invest. 71 : 286-292, August, 2024.
Patients receive doxorubicin IV over 10 minutes and cyclophosphamide IV over 30 minutes on day 1. Treatment repeats every 21 days for 4 courses.
PURPOSE:To provide an external antipruritic agent exhibiting highly excellent antipruritic activity and having long durability by compounding one kind or more of Coptis japonica Makino, Plantago asiatica L., Gardenia jasminoides Ellis and Scutellaria baicalensis Georg. CONSTITUTION:At least one kind of Coptis japonica Makino, Plantago asiatica L., Gardenia jasminoides Ellis and Scutellaria baicalensis Georg. as an active ingredient is decocted with water to give a concentration of 20-70%. The decocted solution can be coated on an itching portion as such or be formed into a preparation such as lotion, cream, liniment or ointment after mixed with the conventional base material or solution. The active ingredients are compounded in an amount of at least 20wt.% on the employment of one kind of the active ingredients and in a total amount of at least 20wt.%, preferably 70-80wt.%, on the employment of two kinds or more thereof. When all of the four kinds are employed, 1-30wt.% of the Coptis japonica Makino, 5-40wt.% of the Plantago asiatica L., 10-50wt.% of the Gardenia jasminoides Ellis and 15-60wt.% of Scutellaria baicalensis Georg. are compounded.
Half of our tDCS responders will be randomized to a group receiving 10 sessions (divided in to two five-day periods) of real tDCS. During real tDCS sessions, subjects will receive stimulation for 20 minutes at a current of 2.0 mA with a 5x5 cm electrode at their optimal responder site previously determined.
The invention aims at providing a traditional Chinese medicinal compound good at treating peptic ulcer. According to the scheme, the traditional Chinese medicinal compound is mainly prepared from the following traditional Chinese medicines by weight: main ingredients: cuttlebone, radix codonopsis, poria, radix paeoniae alba, rhizoma corydalis, frankincense, the myrrh, trogopterus dung, bighead atractylodes rhizome, cassia twig, dried ginger, fructus amomi and radix glycyrrhizae preparata, and an adjuvant material: water. The compound is taken in the form of a decoction which is obtained by decocting the components in the water, and the decoction is continuously taken by two treatment courses. In the period of taking the medicine (the traditional Chinese medicinal compound), a patient should not eat raw or cold and excitant food and food difficult to digest. In the traditional Chinese medicinal compound, the radix codonopsis, the bighead atractylodes rhizome, the poria and liquid of the radix glycyrrhizae preparata are capable of replenishing qi and tonifying spleen; the cassia twig and the radix paeoniae alba, in coordination with the radix glycyrrhizae preparata, have functions of warming middle-jiao and tonifying deficiency, relaxing spasm and relieving pain; the cuttlebone is capable of promoting regeneration of tissue and healing sore, producing acid, relieving pain and stopping bleeding; and the frankincense, the myrrh, the trogopterus dung and the rhizoma corydalis are effective on promoting blood circulation and removing blood stasis. The traditional Chinese medicinal compound, through the combination of the various medicinal components, has functions of tonifying spleen and warming middle-jiao, promoting qi flow and promoting circulation of blood, stopping bleeding and relieving pain, removing blood stasis and promoting tissue regeneration.
Subjects will receive belsomra 20mg before bedtime. In the middle of the night, subjects will be awakened to auditory awakening tones.
Myopia is a public health problem worldwide, especially in some Asian countries like China, Singapore, and Japan. Chinese ocular exercise, originating in 1963 with the theory of Traditional Chinese Medicine, is a kind of massage on acupuncture points around the eye to prevent myopia and alleviate visual fatigue. The exercise has been spread as a community ritual and living habit of primary and high school students for nearly half a century. However, the prevalence of myopia in Chinese children increased remarkably in recent years. Therefore, the efficacy of Chinese ocular exercise on preventing myopia or alleviating visual fatigue is widely questioned. Evidence from clinical trials of high level is needed to clarify that whether Chinese ocular exercise is effective in slowing and preventing myopia progression, or at least in part in easing the symptoms related to myopia and visual fatigue.